L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases

Summary

Comparative evaluation of recurrence-free survival (RFS) time and 3 year overall survival (OS) time between the treatment groups (L-BLP25 plus cyclophosphamide versus placebo and saline infusion).

Timeline

Start

2011-08

Primary completion

2017-12-31

Completion

2018-01-31

Publications

• Schimanski CC, Kasper S, Hegewisch-Becker S, Schroder J, Overkamp F, Kullmann F, Bechstein WO, Vohringer M, Ollinger R, Lordick F, Heinemann V, Geissler M, Schulz-Abelius A, Bernhard H, Schon MR, Greil R, Galle P, Lang H, Schmidtmann I, Moehler M. Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). Oncoimmunology. 2020 Aug 23;9(1):1806680. doi: 10.1080/2162402X.2020.1806680.

Drugs

Indications